tbuckley/cabot-search huggingface dataset:
High Frequency Gain-of-Function Mutation and/or Over-Expression of Proto-Oncogene C-KIT as Major Contributor to the Leukemogenesis in Human Acute Myeloid Leukemia with t(8; 21).
Authors: Guang-Biao Zhou, Yue-Ying Wang, Tong Yin, Xue-Tao Bai, Wen-Xue Liang, Feng Xu, Yi-Wei Liu, Zhu Chen, Sai-Juan Chen
Journal: Blood (2004)
NOVEL Recurrent Genetic Aberrations in Pediatric AML: An AIEOP AML-2002 Study Group.
Authors: Martina Pigazzi, Elena Manara, Valeria Bisio, Sabrina Gelain, Sanja Aveic, Giuseppe Menna, Paolo Pierani, Marco Zecca, Angela Mastronuzzi, Riccardo Masetti, Franco Locatelli, Giuseppe Basso
Journal: Blood (2012)
Prognostic Impact of NOTCH1 Hotspot Mutation in TP53-Mutated Patients with Chronic Lymphocytic Leukemia
Authors: Barbara Kantorova, Jitka Malcikova, Veronika Navrkalova, Jana Smardova, Kamila Brazdilova, Karla Plevova, Eva Diviskova, Marek Borsky, Sarka Pavlova, Nikola Tom, Karol Pal, Martin Trbusek, Alexandra Oltova, Yvona Brychtova, Michael Doubek, Jiri Mayer, Sarka Pospisilova
Journal: Blood (2014)
Y-90-Ibritumomab Tiuxetan, Fluadarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for High-Risk B-Cell Lymphoma
Authors: Ajay K Gopal, Kathrine Guthrie, Joseph Rajendran, John M. Pagel, George Oliviera, David G Maloney, Rainer F. Storb, Oliver W. Press
Journal: Blood (2010)
Quantitative Analysis of Flow Cytometry Immunophenotyping Data for Aiding in the Diagnosis of Myelodysplastic Syndromes (MDS).
Authors: Ha T. Nishino, Youli Zu, Larry Rice, Kelty R. Baker, John J. McCarthy, Gordon Zeng, Uday R. Popat, George Carrum, Chung-Che Chang
Journal: Blood (2004)
Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).
Authors: Michele Cavo, Francesca Patriarca, Paola Tacchetti, Monica Galli, Giulia Perrone, Maria Teresa Petrucci, Annamaria Brioli, Sara Bringhen, Lucia Pantani, Patrizia Tosi, Claudia Crippa, Elena Zamagni, Francesco Di Raimondo, Franco Narni, Claudia Cellini, Michela Ceccolini, Norbert Pescosta, Maria Cecilia Goldaniga, Vittorio Montefusco, Vincenzo Callea, Valerio De Stefano, Tommaso Caravita, Mario Boccadoro, Michele Baccarani
Journal: Blood (2007)
Isolated Subepicardial Right Ventricular Outflow Tract Scar in Athletes With Ventricular Tachycardia
Authors: Jeroen Venlet, Sebastiaan R.D. Piers, Jan D.H. Jongbloed, Alexander F.A. Androulakis, Yoshihisa Naruse, Dennis W. den Uijl, Gijsbert F.L. Kapel, Marta de Riva, J. Peter van Tintelen, Daniela Q.C.M. Barge-Schaapveld, Martin J. Schalij, Katja Zeppenfeld
Journal: Journal of the American College of Cardiology (2017)
Burden, risk factors, and comorbidities of behavioural and emotional problems in Kenyan children: a population-based study
Authors: Symon M Kariuki, Amina Abubakar, Martha Kombe, Michael Kazungu, Rachael Odhiambo, Alan Stein, Charles R J C Newton
Journal: The Lancet Psychiatry (2017)

Three-quarters of the burden of mental health problems occurs in low-and-middle-income countries, but few epidemiological studies of these problems in preschool children from sub-Saharan Africa have been published. Behavioural and emotional problems often start in early childhood, and this might be particularly important in Africa, where the incidence of perinatal and early risk factors is high. We therefore aimed to estimate the prevalence and risk factors of behavioural and emotional problems in young children in a rural area on the Kenyan coast.We did a population-based epidemiological study to assess the burden of behavioural and emotional problems in preschool children and comorbidities in the Kilifi Health and Demographic Surveillance System (KHDSS, a database formed of the population under routine surveillance linked to admissions to Kilifi County Hospital). We used the Child Behaviour Checklist (CBCL) to assess behavioural and emotional problems. We then determined risk factors and medical comorbidities associated with behavioural and emotional problems. The strength of associations between the risk factors and the behavioural and emotional problems was estimated using generalised linear models, with appropriate distribution and link functions.3539 families were randomly selected from the KHDSS. Of these, 3273 children were assessed with CBCL. The prevalence of total behavioural and emotional problems was 13% (95% CI 12-14), for externalising problems was 10% (9-11), and for internalising problems was 22% (21-24). The most common CBCL syndrome was somatic problems (21%, 20-23), whereas the most common DSM-IV-oriented scale was anxiety problems (13%, 12-14). Factors associated with total problems included consumption of cassava (risk ratio 5·68, 95% CI 3·22-10·03), perinatal complications (4·34, 3·21-5·81), seizure disorders (2·90, 2·24-3·77), and house status (0·11, 0·08-0·14). Seizure disorders, burn marks, and respiratory problems were important comorbidities of behavioural and emotional problems.Behavioural and emotional problems are common in preschool children in this Kenyan rural area and are associated with preventable risk factors. Behavioural and emotional problems and associated comorbidities should be identified and addressed in young children.Wellcome Trust.
Life Expectancy in Follicular Lymphoma Is Mainly Determined By Response to First LINE Treatment: A LONG-TERM Survey on 597 Patients
Authors: Corrado Tarella, Angela Gueli, Federica Delaini, Anna Maria Barbui, Riccardo Bruna, Daniele Caracciolo, Daniela Gottardi, Giuseppe Gritti, Roberto Passera, Safaa Ramadan, Andrea Rossi, Alessandro Rambaldi
Journal: Blood (2015)
Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance
Authors: M. Fernández-Ruiz, J. Guinea, D. Lora-Pablos, Ó. Zaragoza, M. Puig-Asensio, B. Almirante, M. Cuenca-Estrella, J.M. Aguado, B. Padilla, P. Muñoz, J. Guinea, J.R. Paño Pardo, J. García-Rodríguez, C.G. Cerrada, J. Fortún, P. Martín, E. Gómez, P. Ryan, C. Campelo, I. de los Santos Gil, V. Buendía, B.P. Gorricho, M. Alonso, F.S. Sanz, J.M. Aguado, P. Merino, F. González Romo, M. Gorgolas, I. Gadea, J.E. Losa, A. Delgado-Iribarren, A. Ramos, Y. Romero, I.S. Romero, O. Zaragoza, M. Cuenca-Estrella, J. Rodríguez-Baño, A.I. Suarez, A. Loza, A.I. Aller García, E. Martín-Mazuelos, M.R. Pérez de Pipaón, J. Garnacho, C. Ortiz, M. Chávez, F.L. Maroto, M. Salavert, J. Pemán, J. Blanquer, D. Navarro, J.J. Camarena, R. Zaragoza, V. Abril, C. Gimeno, S. Hernández, G. Ezpeleta, E. Bereciartua, J.L. Hernández Almaraz, M. Montejo, R.A. Rivas, R. Ayarza, A.M. Planes, I.R. Camps, B. Almirante, J. Mensa, M. Almela, M. Gurgui, F. Sánchez-Reus, J. Martínez-Montauti, M. Sierra, J.P. Horcajada, L. Sorli, J. Gómez, A. Gené, M. Urrea, A. Mularoni, M. Valerio, A. Díaz-Martín, F. Puchades
Journal: Clinical Microbiology and Infection (2017)
Fludarabine, Low Dose Busulfan and Antithymocyte Globulin (ATG) Compared to Fludarabine and Low Dose Total Body Irradiation (TBI) for Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) In Patients with Lymphoid Malignancies.
Authors: Florent Malard, Eolia Brissot, Patrice Chevallier, Thierry Guillaume, Jacques Delaunay, Sameh Ayari, Beatrice Mahe, Viviane Dubruille, Thomas Gastinne, Nicolas Blin, Beatrice Saulquin, jean Luc Harousseau, Philippe Moreau, Noel Milpied, Steven Le Gouill, Mohamad Mohty
Journal: Blood (2010)
Similar Outcomes of Allogeneic Hematopoietic Cell Transplantation from Matched Sibling Donor and Haploidentical Donor for Refractory/Relapsed Acute Myeloid Leukemia
Authors: Dai-Hong Liu, Li Yu, Wenrong Huang, Liping Dou, Honghua Li, Gao Chunji, Bo Jian, Fei Li, Lili Wang
Journal: Blood (2015)
Long-Term Use of Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Chinese Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): MM-024 Expanded Access Program (EAP)
Authors: Xin Du, Jie Jin, Zhen Cai, Fangping Chen, Dao-bin Zhou, Li Yu, Xiaoyan Ke, Xiao Li, Depei Wu, Fanyi Meng, Dena DeMarco, Jingshan Zhang, Jay Mei, Jian Hou
Journal: Blood (2014)
Trainee who paid for escort sex while on duty is allowed to resume practice after suspension
Authors: Clare Dyer
Journal: BMJ (2017)

A trainee anaesthetist who had sex with an escort while on call at a maternity ward will be allowed to resume practice next month when he completes his 10 month suspension from the medical register.

Rupert Pemsel, 33, became the subject of lurid headlines in the tabloid press over his December 2013 tryst with escort Leanne Kennedy, 29, in the on-call room at Princess Anne Hospital in Southampton.

Kennedy and an unnamed younger man …
Status of topoisomerases in pediatric high grade osteosarcomas and their therapeutic and prognostic role
Authors: N. Entz-Werle, E. Guerin, P. Marec-Berard, M. Tabone, C. Schmitt, J. Gentet, H. Pacquement, L. Brugieres, C. Kalifa, A. Babin, M. Gaub
Journal: Journal of Clinical Oncology (2008)

10030 Background: High grade osteosarcomas are the most common malignant bone tumors at adolescence. In the French group, they were treated until 2005 with OS94 guidelines, using a first line therapy of combined high dose-methotrexate and VP16- ifosfamide courses. In the poor response to these drugs, a second line therapy was administered associating doxorubicin and cisplatine. Both therapeutic strategies were based on topisomerase IIα inhibitor. Therefore, a retrospective and prospective molecular study of topoisomerase genes (TOP2A, TOP2B and TOP1) was conducted on diagnostic tumors consecutively collected from this population to understand their therapeutic and prognostic role. Methods: 91 patients were included. Paired normal and tumor biopsy tissues were analyzed by allelotyping, using microsatellites flanking on both sides each locus containing TOP1, TOP2A and TOP2B, coding for topoisomerase genes. These loci are respectively 20q12, 17q21 and 3p24. In addition to these genomic data, quantitative real-time PCR (QPCR) was added to target specifically each gene comparatively to two reference genes (DCK and APP). As frequently co- expressed with TOP2A at 17q21 locus in breast cancer, ERBB2 was also studied by QPCR. Results: Only allelic imbalance were showed by allelotyping but these loci seem to be frequently rearranged : 20q12 is abnormal in 44.4%, 17q21 in 55.3% and 3p24 in 67.5%. QPCR results were concordant with these DNA results, showing mainly gene deletions (22% for TOP1, 34% for TOP2A and 50.5% for TOP2B) and few amplifications (respectively, 14%, 11.5% and 11.5%). No amplification, nor deletion of ERBB2 was detected with QPCR. In a prognostic and therapeutic point of view, amplifications of TOP2A and TOP1 were significantly associated with the group of good responders to chemotherapy (p=0.001 and p=0.064, respectively). Furthermore, a significant prognostic correlation was found between an abnormal TOP2A gene and the overall survival (p=0.045). Conclusions: TOP2A seems to appear at diagnosis as a therapeutic and prognostic marker involved frequently in pediatric high grade osteosarcomas. No significant financial relationships to disclose.
Estimating and accounting for tumor purity in the analysis of DNA methylation data from cancer studies
Authors: Xiaoqi Zheng, Naiqian Zhang, Hua-Jun Wu, Hao Wu
Journal: Genome biology (2017)

We present a set of statistical methods for the analysis of DNA methylation microarray data, which account for tumor purity. These methods are an extension of our previously developed method for purity estimation; our updated method is flexible, efficient, and does not require data from reference samples or matched normal controls. We also present a method for incorporating purity information for differential methylation analysis. In addition, we propose a control-free differential methylation calling method when normal controls are not available. Extensive analyses of TCGA data demonstrate that our methods provide accurate results. All methods are implemented in InfiniumPurify.
Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.
Authors: Karoline V. Gleixner, Matthias Mayerhofer, Karoline Sonneck, Alexander Gruze, Puchit Samorapoompichit, Karl J. Aichberger, Francis Y. Lee, Paul W. Manley, Doriano Fabbro, Winfried F. Pickl, Christian Sillaber, Peter Valent
Journal: Blood (2006)
Efficacy of Novel Agents in Multiple Myeloma in Comparison to Autologous Stem Cell Transplant: A Retrospective Study in a Single Inner City Institution
Authors: Tareq Braik, Dayra Avila, Shivi Jain, Manila Gaddh, Barabara Yim, Peter Ruestow, Shylendra B Sreenivasappa, Shweta Gupta, Sylvia Velinova, Paul G. Rubinstein, Margaret Telfer, Mousami Shah, Thomas Lad, Rosalind Catchatourian
Journal: Blood (2011)
The Significance of Serum Albumin Level and Platelet Count in Patients with Diffuse Large B-Cell Lymphoma in the Context of an Enhanced International Prognostic Index (NCCN-IPI)
Authors: Yotaro Ochi, Yusuke Koba, Yoshimitsu Shimomura, Yuichiro Ono, Nobuhiro Hiramoto, Satoshi Yoshioka, Sumie Tabata, Noboru Yonetani, Akiko Matsushita, Hisako Hashimoto, Yukihiro Imai, Takayuki Ishikawa
Journal: Blood (2015)
Anti-Leukemic Activity of PIK-75, a PI3-Kinase p110α Selective Inhibitor, In Acute Myeloid Leukemia
Authors: François Vergez, Jean-Emmanuel Sarry, Nathalie Gallay, Camille Fialin, Sarah Scotland, Cécile Demur, Peter Shepherd, Gwenn-ael Danet-Desnoyer, Anna Kruczynski, Bernard Payrastre, Stéphane Manenti, Christian Recher
Journal: Blood (2010)
Changes in plasma metabolomic profiles during the first 3 months of androgen-deprivation therapy for prostate cancer.
Authors: Philip James Saylor, Edward D Karoly, Matthew Raymond Smith
Journal: Journal of Clinical Oncology (2012)

116 Background: Androgen-deprivation therapy (ADT) with a GnRH agonist is the foundational systemic therapy for prostate cancer but causes gain of fat mass, loss of muscle mass, adverse changes in serum lipid profile, and a decline in insulin sensitivity. It is unknown whether ADT causes a broader pattern of metabolic alterations. In order to better characterize the metabolic effects of ADT, we measured changes in plasma metabolomic profile during the first 3 months of ADT. Methods: Fasting plasma samples were drawn from 36 subjects at baseline and after 3 months (range: 71-112 days) of GnRH agonist therapy. Metabolomic analyses were performed by Metabolon, Inc (Durham, NC). Extracted samples were split into equal parts for analysis on the gas chromatography/mass spectrometry and liquid chromatography/tandem mass spectrometry platforms. Matched pairs t-test was used to identify biochemicals that differed between baseline and month 3. Results: Of the 504 identified metabolites, 88 changed significantly (p&lt;0.05) from baseline to 3 months. Consistent changes in biochemicals were grouped as follows: (a) Multiple steroids were lower at 3 months, consistent with the effect of therapy on gonadal androgen synthesis. (b) Markers of lipid beta-oxidation (acetyl-carnitines and ketone bodies) and omega-oxidation were lower at 3 months. (c) Two previously-identified biomarkers of insulin resistance (2-hydroxybutyrate and branch chain keto-acid dehydrogenase complex products) were lower at 3 months. (d) Most bile acids and their metabolites were higher during treatment. Cholesterol levels changed very little (1.06 fold change, P = 0.029). Conclusions: Unbiased metabolomic analyses on fasting plasma samples from men receiving GnRH agonist therapy revealed expected, unexpected, and novel results. Steroid levels fell, consistent with the effects of ADT. Biomarkers of lipid metabolism and insulin resistance also fell, unexpected results given that ADT has previously been shown to decrease insulin sensitivity. Finally, we observed evidence of increased levels of bile acids and bile acid metabolites. Further investigation of this novel finding is warranted.
Reoperation in the Treatment of Recurrent Intracranial Malignant Astrocytomas
Authors: Mario Ammirati, Joseph H. Galicich
Journal: Neuro-Oncology (1991)

Fifty-five consecutive patients with recurrent intracranial malignant astrocytomas were reoperated at Memorial Sloan-Kettering Cancer Center from 1972 to 1983. The median survival after reoperation was 36 weeks. Prereoperation Karnofsky rating and extent of surgical resection were the most important independent factors related to survival after reoperation (P < 0.01 and P < 0.05 respectively). Twenty-five patients (45%) had improved Karnofsky ratings after reoperation, and 32 patients (58%) who were independent after reoperation were able to stay so for more than 6 months of their survival time (median value). A patient who does better after reoperation is one with a prereoperation Karnofsky rating of ≥ 70 in whom extensive resection of the tumor is accomplished.
Metastatic renal cell carcinoma (mRCC) in elderly patients: Can a personalized approach be an effective therapeutic option?
Authors: Maria cossu Rocca, Elena Verri, Simona Blotta, Laura Adamoli, Davide Radice, Davide Francesco Riva, Franco Nole
Journal: Journal of Clinical Oncology (2012)

468 Background: Renal cell carcinoma (RCC) is the third most common genitourinary cancer. Up to 30% of patients (pts) with RCC presents with advanced disease. Sunitinib(S), an orally available tyrosine kinase inhibitor, is the well established first-line therapy for these population. Actually few data are available in the literature about its use in patients &gt; 75 yrs investigating the feasibility, the efficacy and the toxicity in this population. Methods: From 2007 to 2011, 16 pts &gt;75 yrs with mRCC received S. 75% of pts had a clear cell carcinoma, 87.5% had a surgery on primary tumor, 18.7% had a metastic disease at diagnosis and the median time to metastatic progression was 13.5 months. Median age was 78 years (range 71-88y).All patients had 0-1 performance status and 69% of them received S as first-line treatment. Four pts started S on the approved 50 mg /d 4-week-on-2-off schedule, but three of them reduced to 37.5 mg continuous once daily dosing(ODD)starting from the third cycle. Five out of 8 pts receiving 37.5 mg continuous ODD reduced the dose at 25 mg continuous ODD or modified the schedule. Four pts started with 25 mg continuous ODD and 2 of them continued the treatment at modified schedule. Median number of cycles administered was 7 (range 2-16). Results: Response rate was 87% (13pts) in 15 evaluable pts. Overall response included 40% (6 pts) of PR, 20% (3pts) of CR, 33% (5pts) of SD &gt; 6 mos. Progressive disease was observed only in 1patient. TTP was 12.4 months (95% CI, 4.8-32.6). Overall survival was 34.2 months (95% CI, 27.3- ). The main toxicity requiring dose reduction or schedule modification was haematological (46%), G3Anemia in 1 pt G3-4 thrombocytopenia in 3pts and G3 leukoneutrophenia in 3pts. No any toxicity required treatment interruption. Conclusions: In summary these results show the feasibility and the efficacy of S in elderly population with high response rate regardless the doses and schedule used.
Baseline demographics of patients with neuroendocrine tumors presenting to seven National Comprehensive Cancer Network (NCCN) institutions: Development of a multi-institutional outcomes database.
Authors: Michael A. Choti, Margaret A. Mayorga, Sarah Bobiak, Matthew Kulke, James C. Yao, Emily K. Bergsland, Eric K. Nakakura, Mark Bloomston, Al Bowen Benson, Manisha H. Shah, Jonathan R. Strosberg
Journal: Journal of Clinical Oncology (2012)

187 Background: Diagnostic strategies, management paradigms, and clinical outcomes of patients with neuroendocrine tumors (NETs) are diverse and poorly characterized. The National Comprehensive Cancer Network (NCCN) created a comprehensive longitudinal database to characterize patients treated for NETs at seven participating institutions. Preliminary results from the database are reported. Methods: Member IRB approval was obtained to identify patients at least 18 years of age presenting to each of seven NCCN institutions between 2004 and 2007 with pathologically confirmed newly or previously diagnosed NETs via hospital medical records. Eligible patients included those with carcinoid (any site); goblet cell or adenocarcinoid; composite carcinoid; poorly differentiated gastrointestinal small cell tumor; pancreatic NET; NET of unknown primary site; pheochromocytoma; and paraganglioma. Baseline demographic characteristics were summarized for this analysis. Results: Among the 2,542 patients identified with a NET diagnosis, patients most frequently presented with carcinoid tumor (51%), pancreatic NET (27%) and NET of unknown primary site (8%). Median age at diagnosis was 55 (SD=13) and median age at first presentation to the NCCN was 57 (SD=13). Fifty-three percent of patients were female. Most (88%) were Caucasian and 8% were African American. Forty percent of patients were diagnosed with NET before presenting to the NCCN. Among these, the median time between initial NET diagnosis and presentation to the NCCN was 2 years (SD=6). Significant differences in provider specialty referral patterns were observed between institutions. Conclusions: The baseline demographic characteristics of NET patients in this new database are consistent with those previously reported in population-based registries. The NCCN database will provide a valuable resource for further exploration of patterns of diagnosis, treatment, consistency with established guidelines, as well as clinical outcomes in patients with this condition. Existing differences among institutions in referral patterns will be further explored.
Identification and Functional Significance of Genes Regulated by Structurally Different ABL Kinase Inhibitors.
Authors: Kousuke Nunoda, Tetsuzo Tauchi, Tomoiku Takaku, Masahiko Sumi, Seiichi Okabe, Goro Sashida, Daigo Akahane, Junko H. Ohyashiki, Kazuma Ohyashiki
Journal: Blood (2005)
TP53 Mutation Is an Independent Predictor of Poor Survival in Untreated Patients with CD20+ Aggressive B-Cell Lymphoma: Analysis within the Ricover-60 Trial
Authors: Thorsten Zenz, Markus Kreuz, Doris Winter, Hanne Helfrich, Maxi Fuge, Heike Horn, Julia Richter, Reiner Siebert, Lorenz Truemper, Norbert Schmitz, Markus Loeffler, Wolfram Klapper, Andreas Rosenwald, Hartmut Döhner, Michael Pfreundschuh, German Ott, Stephan Stilgenbauer
Journal: Blood (2012)
The Marine Tunicate-Derived Cyclic Depsipeptide Aplidin Restores Functional Hematopoiesis in the Marrow of the Gata1low Mouse Model of Myelofibrosis.
Authors: Maria Verrucci, Alessandro Pancrazzi, Fabrizio Martelli, Paola Guglielminelli, Miguel Aracil, Maria Zingariello, Emanuela D'Amore, Jose Jimeno, Alessandro M. Vannucchi, Anna Rita Migliaccio
Journal: Blood (2009)
Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-Versus-Host Disease.
Authors: Weng Jianyu, Xin Du, Xiang Peng, Zhang Xiumin, Suijin Wu, Zesheng Lu, Chengwei Luo, Rong Guo, Chengxin Deng, Wei Ling, Wei Lin, Zilun Huang
Journal: Blood (2007)